Abstract：【Objective】To compare the efficacy of 577 nm laser micropulse mode and 532 nm laser photocoagulation in the treatment of central serous chorioretinopathy (CSC).【Methods】Sixty patients (60 eyes) with CSC diagnosed by fluorescein fundus angiography, indocyanine green angiography and optical coherence tomography (OCT) were selected from September 2021 to August 2023 in our hospital. They were voluntarily divided into the observation group (receiving 577 nm laser micropulse mode treatment) and the control group (receiving 532 nm laser photocoagulation treatment), with 30 cases (30 eyes) in each group. The best corrected visual acuity (BCVA), central macular thickness (CMT) and subfovea choroidal thickness (SCT) and subretinal fluid (SRF) were compared between the two groups before treatment and at 1 month, 3 months and 6 months after treatment.【Results】Compared with before treatment, the BCVA, CMT and SRF heights of both groups were improved (P<0.05) after 1 month of treatment, while SCT was not significantly improved (P>0.05). After 3 months of treatment, SCT decreased in both groups (P<0.05). There was no significant difference in BCVA, CMT and SRF height between the two groups at 1 month, 3 months and 6 months after treatment (P>0.05). There was no significant difference in SCT at 1 month and 6 months after treatment between the two groups (P>0.05). The SCT of the observation group was lower than that of the control group at 3 months after treatment, and the difference was statistically significant (P<0.05). There was no significant difference in SRF absorption rate at 1 month, 3 months and 6 months after treatment between the two groups (P>0.05).【Conclusion】Both 577 nm laser micropulse mode and 532 nm laser photocoagulation can improve visual acuity and reduce the height of CMT and SRF in CSC patients after 1 month. Both laser treatments reduced SCT after 3 months, but the reduction was more pronounced in the 577 nm laser micropulse mode.
彭昕, 李东慧, 蒋倩, 王启常. 577 nm激光微脉冲模式、532 nm激光光凝治疗中心性浆液性脉络膜视网膜病变患者的疗效比较*[J]. 医学临床研究, 2024, 41(11): 1640-1643.
PENG Xin, LI Donghui, JIANG Qian, et al. Comparison of 577 nm Laser Micropulse Mode and 532 nm Laser Photocoagulation in the Treatment of Patients with Central Serous Chorioretinopathy. JOURNAL OF CLINICAL RESEARCH, 2024, 41(11): 1640-1643.
[1] BAE S H, HEO J W, KIM C,et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy[J].Am J Ophthalmol,2011,152(5): 784-792. [2] WANG M, MUNCH I C, HASLER P W, et al. Central serous chorioretinopathy[J].Acta Ophthalmol,2008,86(2): 126-145. [3] LOO R H, SCOTT I U, FLYNN H J, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy[J].Retina,2002,22(1): 19-24. [4] BUJARBORUA D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser[J].Acta Ophthalmol Scand,2001,79(4): 417-421. [5] DARUICH A, MATET A, BEHAR-COHEN F. Central serous chorioretinopathy[J].Dev Ophthalmol,2017,58: 27. [6] SINGH S R, MATET A, van DIJK E, et al. Discrepancy in current central serous chorioretinopathy classification[J].Br J Ophthalmol,2019,103(6): 737-742. [7] LIM J W, KANG S W, KIM Y T, et al. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy[J].Br J Ophthalmol,2011,95(4): 514-517. [8] 徐海军, 周芸芸, 顾国焕. 中药联合532激光光凝治疗急性中心性浆液性脉络膜视网膜病变的临床疗效[J].医学临床研究, 2021,38(10): 1577-1579. [9] HANUMUNTHADU D, TAN A, SINGH S R, et al. Management of chronic central serous chorioretinopathy[J].Indian J Ophthalmol,2018,66(12): 1704-1714. [10] KIM Y J, KIM S Y, HA S, et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years[J].Eye (Lond),2019,33(5): 819-825. [11] KOSS M J, BEGER I, KOCH F H. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy[J].Eye (Lond),2012,26(2): 307-314. [12] 刘培, 安广琪, 张敏, 等. 中心性浆液性脉络膜视网膜病变涡静脉吻合观察[J].中华眼底病杂志, 2023,39(4): 307-311. [13] 刘培, 安广琪, 路晨雨, 等. 中心性浆液性脉络膜视网膜病变患者脉络膜生物标志物改变研究[J].中华眼底病杂志, 2023,39(4): 290-296. [14] 肖蓓, 宋艳萍, 闫明, 等. 涡静脉在中心性浆液性脉络膜视网膜病变发病机制中作用的研究进展[J].中华眼底病杂志, 2024,40(4): 319-323. [15] FUNATSU R, SONODA S, TERASAKI H, et al. Choroidal morphologic features in central serous chorioretinopathy using ultra-widefield optical coherence tomography[J].Graefes Arch Clin Exp Ophthalmol,2023,261(4): 971-979. [16] YADAV N K, JAYADEV C, MOHAN A, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome[J].Eye (Lond), 2015,29(2): 258-264. [17] SCHOLZ P, ERSOY L, BOON C J, et al. Subthreshold Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy[J].Ophthalmologica,2015,234(4): 189-194. [18] LAVINSKY D, PALANKER D. Nondamaging photothermal therapy for the retina: initial clinical experience with chronic central serous retinopathy[J].Retina,2015,35(2): 213-222.
2024, Vol. 41 
